# Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/augmented-her-2-specific-immunity-during-treatment-with-trastuzumab-and/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Clare Taylor,Dawn L. Hershman,Nina Shah,Nicole Suciu‐Foca,Dan P. Petrylak,Robert N. Taub,Linda T. Vahdat,Bin Cheng,Mark D. Pegram,Keith L. Knutson,Raphael Clynes |
| Citations | 214 |
| DOI | 10.1158/1078-0432.ccr-07-0507 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2103118255 |
| PMID | 17785568 |
| Type | article |
| Year | 2007 |

## Paper authors

- [Nina Shah](https://scholariq.org/researchers/nina-shah/)

## Paper journal

- [Clinical Cancer Research](https://scholariq.org/journals/clinical-cancer-research/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.